GLP-1 weight loss timeline: month-by-month expectations in 2026

TLDR. The first month of GLP-1 treatment is mostly nausea, fatigue and a 2 to 5 pound drop. By month 3 the scale has moved 6 to 10 percent of starting body weight. Month 6 is the steady-loss window. Month 12 is the average nadir for semaglutide (14.9 percent loss); tirzepatide patients usually still have room to drop through month 18 (toward 22.5 percent). Year 2 is maintenance. Red flags worth flagging to your prescriber include persistent vomiting beyond week 4, severe abdominal pain, signs of gallbladder disease and complete loss of appetite. Most patients land 60 to 90 percent of the registration-trial mean. This walks through each phase with the typical numbers and the inflection points.

Week 1: starter dose, side effects, very little weight change

You start at 0.25 mg semaglutide or 2.5 mg tirzepatide. These are sub-therapeutic doses chosen to let your gut acclimate before titration. They produce real but modest appetite suppression and a meaningful nausea burden.

What is typical:

• Nausea in the 24 to 72 hours after injection, often worst in the first 24 hours
• Reduced appetite, particularly evening appetite, by day 3 to 5
• 2 to 4 pounds dropped, most of it water and glycogen as caloric intake falls
• Fatigue, especially the day of and the day after injection
• Constipation beginning in days 4 to 7 as gastric motility slows

What is a red flag:

• Vomiting more than twice in 24 hours, or unable to keep liquids down
• Severe upper-abdominal pain radiating to the back (pancreatitis warning sign)
• Right-upper-quadrant pain (gallbladder warning sign)
• Allergic reaction (rash, swelling, breathing difficulty), call 911

What to do: drink water, eat small bland meals (rice, toast, applesauce, banana, plain chicken), avoid high-fat foods, sleep more, do not exercise hard. The body is adjusting to a new hormonal signal; let it.

Week 4: first titration up, second wave of side effects

Standard protocol titrates monthly: 0.25 to 0.5 mg semaglutide, or 2.5 to 5 mg tirzepatide. The dose increase often re-triggers nausea and fatigue for 5 to 10 days after the first injection at the new dose.

What is typical at end of month 1:

• 3 to 7 pounds total loss, or roughly 2 to 3 percent of starting body weight
• Visible appetite suppression: smaller portions feel satisfying, eating between meals is less appealing
• "Food noise" reduction: many patients describe quieter intrusive food thoughts
• Clothing feels marginally different; nobody else has noticed yet

What is a red flag:

• Zero weight loss with full medication adherence: usually means you are eating more than the medication's appetite suppression is offsetting. Add a food log and discuss with your prescriber.
• 10-plus pounds lost in the first month: too fast. Aggressive early losses correlate with worse long-term retention and more lean-mass loss. Consider slowing the titration.
• New right-upper-quadrant pain after a fatty meal: possible gallbladder, get an ultrasound

If side effects from the 0.5 mg semaglutide or 5 mg tirzepatide dose are intolerable, holding at the previous dose for an extra month is acceptable and does not hurt long-term outcomes. See our titration guide.

Month 2 to 3: titration to a therapeutic dose, the real efficacy window opens

By end of month 3, you should be at 1.0 mg semaglutide or 7.5 mg tirzepatide, both of which are at the lower edge of therapeutic. Side effects from each titration step typically last 5 to 14 days and then subside.

What is typical at end of month 3:

• 6 to 10 percent cumulative weight loss, or 12 to 22 pounds for a 200-pound starter
• Clothing changes: looser fit, dropping a size in some garments
• Visible changes to others: people start noticing, sometimes commenting
• Energy returning as the body adjusts to the new caloric intake
• Some fading of the strongest "food noise" suppression; the effect remains but is less novel

What to discuss with your prescriber at the 3-month visit:

• Are you on track? 6 to 10 percent at 3 months is the target. Substantially less (3 percent or below) is a flag.
• Are side effects acceptable? Continued daily nausea at month 3 is a flag.
• Is the dose right? Some patients respond strongly to 1.0 mg semaglutide and do not need to titrate to 1.7 or 2.4.
• Lab work: A1c, lipid panel, metabolic panel at month 3 or month 6.

Month 4 to 6: the steady-loss window, biggest results

This is the most productive phase. You are on a therapeutic dose. Side effects are usually manageable. The appetite suppression is doing the work and you are still seeing scale movement weekly.

What is typical at end of month 6:

• 12 to 15 percent cumulative weight loss on semaglutide
• 15 to 20 percent cumulative weight loss on tirzepatide
• For a 200-pound starter: 24 to 40 pounds total, depending on drug and dose
• First plateau often appears around month 5 to 6, lasting 4 to 8 weeks before the curve resumes
• Clothing two sizes smaller; visible facial changes; energy higher than baseline

What to discuss at the 6-month visit:

• Do you want to titrate to the maximum dose, or hold at a sub-maximum dose? The trial data shows similar long-term outcomes at lower doses for many patients with fewer side effects.
• If you have hit a plateau, is it stalling at a satisfactory weight or do you want to push lower? See our plateau guide.
• How is your protein intake and resistance training? This is the lean-mass-protection window.
• Repeat labs: A1c, lipids, metabolic panel.

Month 7 to 12: diminishing-returns phase, decisions on dose

The weight-loss rate slows. You are still losing, but maybe 0.5 to 1 pound per week instead of the 2 to 3 pounds per week of months 2 to 4. This is expected biology, not failure. The body is approaching a new energy balance and metabolic adaptation is reducing the size of the deficit the medication maintains.

What is typical at month 12:

• 14 to 15 percent cumulative loss on semaglutide (the STEP-1 mean was 14.9 percent)
• 20 to 22 percent cumulative loss on tirzepatide (the SURMOUNT-1 mean at 15 mg was 22.5 percent)
• For a 200-pound starter, ending body weight 156 to 172 pounds depending on drug
• Visible body-composition changes if resistance training has been consistent
• Stabilization on a long-term dose; for many, that is a sub-maximum dose

If you are below trial means at month 12, you are not failing. Trial means include patients on maximum doses with intensive trial-level support. Real-world cohorts land somewhere between 60 and 90 percent of trial means. Around 10 to 15 percent of patients are "super-responders" who exceed trial means; 10 to 15 percent are non-responders who lose under 5 percent. Both ends are normal distribution edges.

For non-responders, the conversation at month 12 is whether to switch drug class. Patients who plateau early on semaglutide often respond to tirzepatide, because tirzepatide acts on both GLP-1 and GIP receptors. See our Wegovy vs Zepbound comparison for the head-to-head data.

Month 13 to 18: maintenance window for semaglutide, continued loss for tirzepatide

Most semaglutide patients reach their nadir between months 12 and 18. Most tirzepatide patients continue losing through months 18 to 24, because the SURMOUNT-1 curve was still descending at 72 weeks.

What is typical:

• Semaglutide: weight stable or 1 to 3 percent additional loss through month 18
• Tirzepatide: continued slow loss of 1 percent per month through month 24
• Maintenance dose decisions: some patients step down from 2.4 mg semaglutide to 1.7 or 1.0 mg as maintenance, but the data on this is observational
• Lifestyle becomes more important: the medication is no longer creating new loss, so behavioral patterns determine whether you stabilize or drift

What to discuss: the long-term plan. Are you staying on the same dose? Stepping down? Tapering? See our maintenance article.

Year 2 and beyond: maintenance reality

The SELECT trial (NEJM 2023) showed 9.4 percent mean weight loss sustained at 4 years among patients staying on semaglutide. This is below the year-1 peak of 14.9 percent, meaning some regain occurred even on continued treatment. Patients regain about 3 to 5 percent of body weight between year 1 and year 4 on continued medication.

What is typical year 2-plus:

• Stable weight within 5 to 8 percent of nadir for most patients
• Maintenance challenges: appetite returning slowly, food-noise reduction less pronounced, lifestyle drift
• Long-term safety profile: gallbladder events accumulate slightly with longer exposure; metabolic markers (A1c, lipids, blood pressure) generally remain improved
• Cost: same as year 1, unless generic semaglutide arrival (expected 2027) drops branded prices

Patients who stop at year 2 typically regain to 80 to 100 percent of their original starting weight within 18 months of stopping, with worse body composition (more fat, less lean). See our discontinuation article for the detailed regain curve.

The honest cohort split

One thing the trial means hide is how bimodal the distribution actually is. At 12 months:

• About 15 percent of patients lose less than 5 percent of body weight (non-responders)
• About 30 percent lose 5 to 10 percent
• About 35 percent lose 10 to 15 percent
• About 20 percent lose more than 15 percent

For tirzepatide, the curve shifts right: more patients in the 15-plus percent bucket, fewer non-responders. If you are in the 5 to 10 percent bucket at 12 months on semaglutide, switching to tirzepatide often produces another 5 to 10 percent in the second year.

Red flags by phase

What to do alongside the medication

The patients who land in the upper end of the response distribution share four habits:

1. Protein intake at 1.0 to 1.2 g per kg of target body weight, daily
2. Resistance training 2 to 3 times weekly, sustained throughout treatment
3. Hydration: 2.5 to 3 liters daily to manage constipation and offset appetite-driven thirst confusion
4. Sleep: 7-plus hours nightly; sleep deprivation amplifies every GLP-1 side effect and increases regain risk

None of these are unique to GLP-1 patients. They are the same habits that produce the best outcomes across every weight-loss intervention. The medication amplifies their effect; it does not replace them.

FAQ

Is it normal to plateau at month 6?

Yes. The first plateau commonly arrives between months 5 and 7 and lasts 4 to 8 weeks. The curve usually resumes downward at a slower rate. A plateau lasting more than 12 weeks is worth discussing with your prescriber: it may indicate dose insufficiency, behavioral drift or that you have reached your individual response ceiling on the current drug. See our plateau guide.

Should I weigh myself daily?

Most clinicians recommend weekly, not daily. Daily weighing introduces noise from hydration, sodium intake, glycogen and bowel patterns that obscures the actual fat-loss trend. Once weekly, at the same time of day, after the same routine (typically Friday or Sunday morning) gives you a cleaner signal.

How long do GI side effects last?

For most patients, daily-noticeable side effects fade by week 8 to 12. Each titration step typically produces 5 to 14 days of renewed side effects that then subside. Persistent nausea past month 4 at a stable dose is unusual and worth a prescriber conversation.

Can I drink alcohol on a GLP-1?

The official label position is that no specific contraindication exists. In practice, alcohol tolerance drops sharply on GLP-1 medication. Patients commonly report being intoxicated on half their usual intake. Alcohol also amplifies nausea and dehydration. Most patients reduce alcohol substantially during treatment, not because they are told to but because they no longer enjoy it the same way.

What happens if I miss a dose?

For weekly drugs (semaglutide, tirzepatide), if you remember within 5 days of the missed dose, take it as soon as possible and continue the original schedule. If more than 5 days have passed, skip the missed dose and resume your normal schedule. Do not double up. Missing a single dose typically does not affect the response curve; missing several doses can require a short re-titration if your gastrointestinal tolerance drops.